Nordics

Three regional dynamics stand out in the Nordics this quarter.

First, the region is converging on a two-track model: classical psychedelics remain controlled and research-only, while ketamine/esketamine is being absorbed into specialist psychiatry and health-technology appraisal. Sweden’s updated treatment recommendations for depression, anxiety and obsessive-compulsive disorders explicitly mention esketamine as an additional option for severe treatment-resistant depression, which reinforces the medicalisation of the field rather than any move towards broad access. Denmark’s access profile is even more explicit, with LSD on List A and psilocybin, MDMA, DMT, 5-MeO-DMT, mescaline, ibogaine and ketamine on List B, meaning use is restricted to medical and scientific purposes, while esketamine is the clearest authorised psychiatric route. In Norway, DMP’s 2025 and 2026 health-technology-assessment work on intravenous ketamine for treatment-resistant depression, plus a separate project-plan on ketamine for acute suicidal ideation, shows that the question is shifting from legality to service design and reimbursement. Finland and Iceland, meanwhile, still present as narrow, regulated access environments, with esketamine the visible medicine pathway and classical compounds limited to research or special authorisation.

Second, the clinical centre of gravity is still Copenhagen and Stockholm, but the Nordic trial footprint is now better described as a distributed specialist cluster than a single-country story. Blossom tracks 8 psychedelic clinical trials connected to Sweden and 10 connected to Finland, with Denmark’s Copenhagen programme standing out as the region’s most coherent disease-specific platform, especially in alcohol use disorder. The Danish open-label psilocybin work and the larger Quantum Trip Trial are important not because they signal access, but because they show that Nordic investigators are willing to build large, methodologically serious studies around a topic that has been dominated elsewhere by small proof-of-concept datasets. In Sweden, the visible trial mix spans esketamine, ketamine and psilocybin, and in Finland the portfolio similarly spans esketamine, ketamine and psilocybin across TRD, MDD and alcohol use disorder. The regional implication is that Nordic sites are increasingly contributing to the kinds of studies that can support later comparative-effectiveness and reimbursement debates.

Third, the Nordics are becoming more policy-conscious about the boundary between hospital use and off-label expansion. That boundary matters because it is where psychedelic medicine is most likely to move, if it moves at all. Sweden’s health-authority language around esketamine, Denmark’s Medicinraadet recommendation for a defined treatment-resistant depression subgroup, and Norway’s assessment work all point to a cautious but real willingness to evaluate specialist interventions on evidence and service burden rather than ideology. This does not equal liberalisation. It does mean the region is building the regulatory and economic vocabulary needed for narrow adoption, should later trial read-outs justify it. That is especially relevant in Denmark, where Copenhagen’s research ecosystem is unusually integrated across university psychiatry and hospital practice, and in Norway, where DMP’s faster 2025 appraisal cycle may shorten the path from evidence to policy if a ketamine or esketamine submission reaches a favourable endpoint.

A fourth, quieter dynamic is that the Nordics are under-invested in public-facing psychedelic access, but not under-invested in infrastructure. Norway’s annual report stresses faster method assessments and shorter timelines for hospital medicines, which matters even when the topic is not explicitly psychedelic. Sweden’s recent treatment guidance update shows that national expert groups remain engaged. Finland’s ecosystem data also shows stakeholders and events around a relatively small trial base, suggesting a modest but persistent community rather than a dormant one. For investors and policy analysts, this matters because the region may not generate large patient-access revenues soon, but it is well placed to produce high-quality comparative evidence, service models and reimbursement precedents.

Taken together, the Nordic picture is one of controlled continuity with selective professionalisation. The region is not moving towards adult-use or broad compassionate-access models. Instead, it is creating a more credible pathway for hospital-based ketamine and esketamine, while classical psychedelics continue to advance only through carefully framed trials. That combination makes the Nordics less of a near-term commercial growth story and more of a medium-term evidence-and-policy story, with Copenhagen, Stockholm and Oslo the places to watch.

Over the next 12 to 24 months, the most likely Nordic change is not a dramatic regulatory opening, but further institutionalisation of specialist pathways. Norway is the clearest near-term watchpoint: if DMP’s ketamine assessment work converts into a practical policy recommendation, it could become the region’s most important reimbursement precedent for hospital-based psychedelic-adjacent care. Sweden is likely to remain selective but active, with esketamine embedded in specialist psychiatry and national treatment guidance continuing to frame the field in terms of severe, treatment-resistant illness rather than broad access. Denmark should remain the region’s most research-visible market, especially if the Copenhagen alcohol-use-disorder programme produces more publication flow, because that would give Nordic policymakers a stronger evidence base in a non-depression indication.

Finland and Iceland are likely to stay smaller in absolute terms, but neither should be discounted. Finland’s trial base suggests a steady, if limited, research ecosystem that can support replication studies or multi-site collaboration. Iceland’s role is likely to remain cautious and narrow, with approved medicine access more salient than classical psychedelic development. Across the region, the important signal is that guideline committees, health-technology agencies and hospital systems are engaging the topic in a way that could, over time, normalise narrow specialist use. That still leaves access highly constrained, but it also means the Nordics may be better prepared than many regions if later trial read-outs support a more formal place for ketamine, esketamine or, further out, selected classical psychedelic therapies in specialist care.